Merck & Co. has yet to report first-quarter earnings, so industry watchers still don’t know exactly how much market share the company’s new hep C combo treatment, Zepatier, has scored since winning approval in late January. But so far, comments from its competitors suggest it’s doing pretty well for itself.
The pharma giant’s pricing strategy on its new cocktail has made it a thorn in the side for both Gilead Sciences ($GILD) and AbbVie ($ABBV), its main competitors--both of which reported lower-than-expected hep C sales for the period.
Read Full Article »